Evidence map›Paper›PMID 42470642›Full record

ArticleSTAR protocols2026

Protocol for high-throughput droplet-engineered TIL-retaining tumor organoids in triple-negative breast cancer.

Xiaolong Zhou, Yu Zhu, Wanlong Wang, Yongde Cai, Zhiyuan Liu, Yingshi Su, Shaohua Ma

Abstract read
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaolong ZhouTsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen 518055, China.
Yu ZhuTsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen 518055, China.
Wanlong WangTsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen 518055, China; Synorg Biotechnology (Shenzhen) Co. Ltd., Shenzhen 518107, China.
Yongde CaiSynorg Biotechnology (Shenzhen) Co. Ltd., Shenzhen 518107, China.
Zhiyuan LiuSynorg Biotechnology (Shenzhen) Co. Ltd., Shenzhen 518107, China.
Yingshi SuSynorg Biotechnology (Shenzhen) Co. Ltd., Shenzhen 518107, China.
Shaohua MaTsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen 518055, China; Key Laboratory of Industrial Biocatalysis, Ministry of Education, Tsinghua University, Beijing 100084, China; Key Lab of Active Proteins and Peptides Green Biomanufacturing of Guangdong Higher Education Institutes, Tsinghua Shenzhen International Graduate School, Shenzhen 518055, China. Electronic address: ma.shaohua@sz.tsinghua.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we present a protocol for generating high-throughput, droplet-engineered tumor organoids from triple-negative breast cancer (TNBC) tissues using the OrgFab® micro-sphere printing system. We describe tumor dissociation, bioink preparation, and automated organoid fabrication. We further detail rho-associated coiled-coil kinase (ROCK) pathway modulation to preserve tumor-infiltrating lymphocytes (TILs) and enhance T cell function, as well as flow cytometry-based immune characterization (Figure 1). This protocol enables scalable production of immune-competent tumor organoids for immunological analysis and drug-screening applications. For complete details on the use and execution of this protocol, please refer to Zhou et al.

Indexed as

Biotechnology and bioengineeringCancerOrganoids

Identifiers

PMID42470642
PMCPMC13400659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.